سعر سيبليوم 5مجم 18 كبسولة 2023

Flunarizine 5 mg capsules, pack of 18 (3 strips) (Sibelium, Janssen-Cilag); selective calcium-entry blocker listed in Egypt as an antimigraine agent.

• Very common: weight gain. Common: increased appetite, rhinitis, depression, sleep problems or somnolence, nausea, constipation, abdominal pain/dyspepsia, myalgia, breast pain, menstrual irregularity and fatigue.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Extrapyramidal effects (slowness, rigidity, tremor, involuntary movements of the face, mouth or tongue), paraesthesia, tinnitus, galactorrhoea and severe allergic reactions (angioedema) have also been reported.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Do not use with known hypersensitivity to flunarizine or any excipient, in patients with a depressive illness or history of recurrent depression, or in patients with Parkinson's disease or similar (extrapyramidal) disorders.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Fatigue may occur during treatment; treatment may need to be stopped or the dose reduced. Women with previous depressive illness may be more likely to become depressed again with long-term use.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Elderly patients: flunarizine may give rise to depressive illness, Parkinson's disease or similar disorders.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• May cause drowsiness; do not drive or use machines if affected. Avoid alcohol, which increases drowsiness. Taking more than the recommended amount increases the risk of side effects.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

• Tranquillisers / hypnotics and alcoholAdditive drowsiness.Health Products Regulatory Authority (HPRA), Ireland
• Oral contraceptivesGalactorrhoea may occur in the first two months of treatment.Health Products Regulatory Authority (HPRA), Ireland
• Antihypertensive medicinesThe antihypertensive dose may need adjustment.Health Products Regulatory Authority (HPRA), Ireland

• Not recommended during pregnancy.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland
• Do not breast-feed during treatment, as small amounts may pass into breast milk.General active-ingredient information · Health Products Regulatory Authority (HPRA), Ireland

English text not available for this section.